Astellas Pharma US, Inc. announced that Vaprisol(R) (conivaptan hydrochloride injection) Premixed in 5% Dextrose, a new premixed formulation approved by the US FDA in October 2008 is commercially available now.

Discovered and developed by Astellas, Vaprisol, an arginine vasopressin (AVP) receptor antagonist, is the first and only approved drug indicated for the treatment of both euvolemic and hypervolemic hyponatremia in hospitalized patients.

Hyponatremia is a potentially life-threatening condition that occurs when the body's blood sodium level falls significantly below normal.

"It is imperative to promptly address hyponatremia in emergency and hospital settings," said Dr. Joseph Verbalis, M.D., Professor of Medicine and Physiology at Georgetown University. "Vaprisol Premixed in 5% Dextrose is a convenient option for quickly preparing treatment for hyponatremia patients."

Comments

Search RSS

All rights reserved."